Biosimilars? The Blockbusters behind the Blockbusters
VelaLabs - A Tentamus Company
(PresseBox) - The biosimilar market is steadily expanding and for some companies and their originator molecules the market is or will be soon crowded and competitive. The next few years will be very exciting in respect of how many biosimilars, especially monoclonal antibodies, developingcompanies will have commercial success within one specific originator segment - products, where essential patents will expire now or in the near future.
VelaLabs?s Support for International Clients
Within the Tentamus Group, VelaLabs is specialized for characterization of biosimilars and supports its customers with complete analytics and tools for nearly all biomolecules. All dedicated methods are either routinely established or will be developed upon client request. A typical panel of methods is shown e.g. for trastuzumab (originator product already on the market: Herceptin
Moreover, VelaLabs has considerable background knowledge with respect to mode-of action, comparability studies, patent & market situation, post approval activities, and the highly competitive field for these biomolecules. For more than 20 blockbuster drugs, VelaLabs has compiled fact sheets, which are free for download (from their website) for our clients and other interested parties.
See our abstract:
Biosimilars ? A growing business segment in the near future
(Zimmermann, Fido et al)
For any more information, consultations or questions please contact Flora Rostemi (f.rostemi(at)vela-labs.at)
Tentamus Group GmbH was founded in 2011. Tentamus is a global product and safety group with a core presence in Europe, UK, Israel, China and the USA. Accredited and licensed Tentamus Group tests, audits and consults on all products involving the human body (food & feed, pharmaceuticals & medical, agrochemicals, cosmetics, agriculture & environment and nutraceutical & supplements). Tentamus Group is represented in over 40 locations worldwide. More than 1,600 highly-trained staff members work in over 1 million square feet of laboratory and office spaces. For further information please visit www.tentamus.com.
Tentamus Group
An der Industriebahn 5
13088 Berlin, Germany
www.tentamus.com
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Tentamus Group GmbH was founded in 2011. Tentamus is a global product and safety group with a core presence in Europe, UK, Israel, China and the USA. Accredited and licensed Tentamus Group tests, audits and consults on all products involving the human body (food&feed, pharmaceuticals&medical, agrochemicals, cosmetics, agriculture&environment and nutraceutical&supplements). Tentamus Group is represented in over 40 locations worldwide. More than 1,600 highly-trained staff members work in over 1 million square feet of laboratory and office spaces. For further information please visit www.tentamus.com.Tentamus GroupAn der Industriebahn 513088 Berlin, Germanywww.tentamus.com
Datum: 26.07.2018 - 01:00 Uhr
Sprache: Deutsch
News-ID 1538973
Anzahl Zeichen: 2761
contact information:
Contact person:
Town:
Vienna
Phone:
Kategorie:
Energy & Utilities
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 444 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Biosimilars? The Blockbusters behind the Blockbusters
"
steht unter der journalistisch-redaktionellen Verantwortung von
Tentamus Group GmbH (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
